Paul J Martin

Q: What Schools Are Affiliated With Paul J Martin

Paul J Martin is affiliated with the following schools: University of California, Berkeley, Stanford University, University of Washington, National Taiwan University

Paul J Martin's AcademicInfluence.com Rankings

Paul J Martin

Engineering

#5779

World Rank

#7052

Historical Rank

Electrical Engineering

#1642

World Rank

#1740

Historical Rank

engineering Degrees

Paul J Martin

Computer Science

#7452

World Rank

#7849

Historical Rank

Computational Linguistics

#1485

World Rank

#1501

Historical Rank

Machine Learning

#2747

World Rank

#2782

Historical Rank

Artificial Intelligence

#3041

World Rank

#3087

Historical Rank

computer-science Degrees

Download Badge

Engineering
Computer Science

Paul J Martin's Degrees

PhD Computer Science Stanford University
Masters Electrical Engineering University of California, Berkeley
Bachelors Computer Engineering University of California, Berkeley

Similar Degrees You Can Earn

Best Online PhD of Computer Science (Doctorates) 2026

Why Is Paul J Martin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Paul J Martin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. (2005) (3030)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease (2015) (2244)
Reduced mortality after allogeneic hematopoietic-cell transplantation. (2010) (1297)
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. (2002) (935)
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. (2003) (566)
Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. (2011) (525)
Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. (2003) (469)
First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. (2012) (459)
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. (2006) (440)
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. (2003) (395)
Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. (2002) (389)
Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. (2005) (383)
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. (2009) (347)
Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. (2014) (324)
Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. (2004) (320)
Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts (1985) (309)
Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. (2010) (303)
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. (2006) (299)
Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. (2015) (283)
Duration of immunosuppressive treatment for chronic graft-versus-host disease. (2004) (272)
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. (2002) (269)
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. (2017) (267)
Limits of HLA mismatching in unrelated hematopoietic cell transplantation. (2004) (265)
Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. (2015) (264)
Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. (2003) (259)
Involvement of the B-lymphoid system in chronic myelogenous leukaemia (1980) (254)
Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. (2002) (253)
How we treat chronic graft-versus-host disease. (2015) (234)
Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. (2003) (233)
Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. (2005) (231)
Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. (2009) (226)
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. (2007) (217)
High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. (2003) (216)
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. (2002) (210)
Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. (2008) (205)
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. (2011) (203)
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. (2003) (197)
NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. (2015) (189)
A Risk Score for Mortality after Allogeneic Hematopoietic Cell Transplantation (2006) (185)
Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. (2013) (183)
SIROLIMUS (RAPAMYCIN) FOR THE TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE1 (2001) (182)
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. (2017) (177)
THE USE OF RADIOLABELED ANTI‐CD33 ANTIBODY TO AUGMENT MARROW IRRADIATION PRIOR TO MARROW TRANSPLANTATION FOR ACUTE MYELOGENOUS LEUKEMIA (1992) (175)
A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. (2015) (167)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. (2015) (164)
Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. (2016) (161)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. (2006) (160)
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. (2002) (158)
MHC Haplotype Matching for Unrelated Hematopoietic Cell Transplantation (2007) (154)
Airflow Decline after Myeloablative Allogeneic Hematopoietic Cell Transplantation: The Role of Community Respiratory Viruses (2006) (151)
Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. (2004) (150)
The biological significance of HLA‐DP gene variation in haematopoietic cell transplantation (2001) (149)
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. (2006) (144)
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. (2009) (144)
Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. (2003) (138)
Allogeneic hematopoietic stem cell transplantation for myelofibrosis. (2003) (136)
Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. (2016) (134)
Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. (2002) (123)
A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. (2005) (123)
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. (2009) (117)
An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. (2006) (116)
Use of fluid-ventilated, gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease. (2006) (116)
Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. (2007) (114)
HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation. (2012) (112)
Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. (2009) (111)
Biomarker Panel for Chronic Graft-Versus-Host Disease. (2016) (107)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. (2015) (107)
Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. (2011) (106)
Cardiovascular Hospitalizations and Mortality Among Recipients of Hematopoietic Stem Cell Transplantation (2011) (105)
Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. (2012) (104)
Hematopoietic stem cell transplants from unrelated donors (1997) (103)
What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants ? (1990) (102)
Graft‐versus‐host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long‐term follow‐up of a controlled trial (1989) (102)
CD28-Specific Antibody Prevents Graft-Versus-Host Disease in Mice1 (2000) (101)
Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003–2007 Versus 2013–2017 Cohorts (2020) (101)
Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. (2016) (100)
Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. (2015) (100)
Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long‐term follow‐up (2005) (99)
Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. (2014) (97)
Evaluation of published single nucleotide polymorphisms associated with acute GVHD. (2012) (94)
Delivering care to long-term adult survivors of hematopoietic cell transplantation. (2012) (92)
Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. (2013) (92)
Association between pretransplant interferon-α and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase (1998) (90)
Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice. (2002) (90)
Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. (2012) (89)
Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. (2014) (88)
Treatment of chronic graft-versus-host disease: Past, present and future (2011) (88)
Prognostic factors and outcomes of severe gastrointestinal graft-vs.-host disease after allogeneic hematopoietic cell transplantation (2014) (87)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. (2015) (86)
Monoclonal antibodies identifying a novel T-Cell antigen and Ia antigens of human lymphocytes (1980) (86)
Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease (2009) (86)
Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. (2014) (85)
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. (2006) (85)
A survey of diagnosis, management, and grading of chronic GVHD. (2002) (85)
Host T Cells Resist Graft-Versus-Host Disease Mediated by Donor Leukocyte Infusions1 (2000) (85)
Validation of measurement scales in ocular graft-versus-host disease. (2012) (83)
Monoclonal antibody 9.3 and anti‐CD11 antibodies define reciprocal subsets of lymphocytes (1985) (83)
Late cardiovascular complications after hematopoietic cell transplantation. (2014) (82)
Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. (2014) (82)
Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. (2012) (80)
Resilience, health, and quality of life among long‐term survivors of hematopoietic cell transplantation (2015) (79)
Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease. (2017) (78)
Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. (2002) (78)
Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. (2011) (77)
A Phase 3 randomized study of Remestemcel-L versus placebo added to second line therapy in patients with steroid refractory acute graft versus host disease. (2020) (75)
Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. (2013) (74)
Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation. (2017) (74)
Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. (2005) (74)
Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. (2014) (72)
PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells (2017) (71)
CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens. (2004) (70)
Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial (2015) (68)
A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation (2015) (67)
Therapy with mycophenolate mofetil for refractory acute and chronic graft-versus-host disease (2009) (66)
Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice. (2016) (66)
Disparity for a newly identified minor histocompatibility antigen, HA‐8, correlates with acute graft‐versus‐host disease after haematopoietic stem cell transplantation from an HLA‐identical sibling (2003) (66)
Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. (2004) (65)
Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. (2016) (64)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multinational Trial of Iseganan for the Prevention of Oral Mucositis in Patients Receiving Stomatotoxic Chemotherapy (PROMPT-CT Trial) (2003) (63)
Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. (2002) (63)
Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. (2014) (62)
A novel soluble form of Tim-3 associated with severe graft-versus-host disease. (2013) (61)
Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. (2002) (61)
Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. (2009) (61)
Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. (2019) (61)
Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation. (2011) (61)
Enhanced T-cell reconstitution by hematopoietic progenitors expanded ex vivo using the Notch ligand Delta1. (2006) (60)
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. (2005) (60)
HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category. (2010) (59)
Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. (2013) (58)
Biology of chronic graft-versus-host disease: implications for a future therapeutic approach. (2008) (58)
Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life. (2015) (58)
TREATMENT OF ACUTE GRAFT‐VERSUS‐HOST DISEASE WITH A NONMITOGENIC ANTI‐CD3 MONOCLONAL ANTIBODY (1992) (58)
A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. (2004) (56)
Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. (2015) (56)
Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. (2012) (54)
Factors associated with adherence to preventive care practices among hematopoietic cell transplantation survivors. (2011) (54)
The absence of platelet-derived growth factor-B in circulating cells promotes immune and inflammatory responses in atherosclerosis-prone ApoE-/- mice. (2005) (53)
A PHASE I‐II STUDY EVALUATING THE MURINE ANTI‐IL-2 RECEPTOR ANTIBODY 2A3 FOR TREATMENT OF ACUTE GRAFT‐VERSUS-HOST DISEASE (1990) (52)
Signal transduction by HLA class II antigens expressed on activated T cells (1991) (52)
Secondary treatment of acute graft-versus-host disease: a critical review. (2012) (52)
Risk factors for depression and fatigue among survivors of hematopoietic cell transplantation (2016) (51)
Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. (2009) (51)
A guide to research partnerships for pragmatic clinical trials (2014) (50)
Assessment of Joint and Fascia Manifestations in Chronic Graft‐Versus‐Host Disease (2014) (49)
Clinical benefit of response in chronic graft-versus-host disease. (2012) (47)
Homotypic aggregation of human cell lines by HLA class II‐, class Ia‐ and HLA‐G‐specific monoclonal antibodies (1991) (47)
Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. (2008) (47)
Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. (2017) (47)
Effects of race on survival after stem cell transplantation. (2005) (47)
Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. (2008) (46)
Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation (2010) (46)
Diagnosis and clinical management of chronic graft-versus-host disease (2004) (44)
Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age. (2010) (43)
An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. (2017) (43)
Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. (2011) (42)
Multi‐centre validation of the prognostic value of the haematopoietic cell transplantation‐ specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation (2015) (42)
Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease (2017) (41)
An online randomized controlled trial, with or without problem-solving treatment, for long-term cancer survivors after hematopoietic cell transplantation (2018) (41)
Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation. (2013) (40)
Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. (2017) (40)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report (2021) (40)
Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. (2006) (39)
Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. (2010) (39)
Involvement of Donor T-Cell Cytotoxic Effector Mechanisms in Preventing Allogeneic Marrow Graft Rejection (1998) (38)
CD28 Signal Enhances Apoptosis of CD8 T Cells After Strong TCR Ligation 1 (2003) (38)
Current challenges in chronic graft-versus-host disease. (2010) (38)
Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors. (2014) (37)
Prognostic relevance of ‘early‐onset’ graft‐versus‐host disease following non‐myeloablative haematopoietic cell transplantation (2005) (37)
Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. (2007) (37)
Anti-CD3ε F(ab′)2 Prevents Graft-Versus-Host Disease by Selectively Depleting Donor T Cells Activated by Recipient Alloantigens1 (2001) (37)
Extending Postgrafting Cyclosporine Decreases the Risk of Severe Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation (2006) (37)
A phase I / II trial of iodine-131 – tositumomab ( anti-CD 20 ) , etoposide , cyclophosphamide , and autologous stem cell transplantation for relapsed B-cell lymphomas (2000) (36)
Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation. (2015) (36)
Lung function and long-term complications after allogeneic hematopoietic cell transplant. (2010) (35)
Langerhans Cell Homeostasis and Turnover After Nonmyeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation (2014) (35)
Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium. (2013) (35)
Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation (2009) (35)
Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. (2016) (34)
A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells. (2011) (34)
IL10 and IL10 Receptor Gene Variation and Outcomes After Unrelated and Related Hematopoietic Cell Transplantation (2009) (34)
Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin. (2005) (33)
How I treat steroid-refractory acute graft-versus-host disease. (2020) (33)
Prognostic utility of routine chimerism testing at 2 to 6 months after allogeneic hematopoietic cell transplantation. (2009) (33)
Bandage Soft Contact Lenses for Ocular Graft-versus-Host Disease. (2015) (32)
ORAL BECLOMETHASONE DIPROPIONATE FOR TREATMENT OF HUMAN INTESTINAL GRAFT‐VERSUS-HOST DISEASE (1995) (32)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. (2021) (32)
Simultaneous genotyping of single nucleotide polymorphisms in the IL-1 gene complex by multiplex polymerase chain reaction-restriction fragment length polymorphism. (2002) (31)
Visual Acuity and Anterior Segment Findings in Chronic Graft-Versus-Host Disease (2011) (31)
Spiritual or religious struggle in hematopoietic cell transplant survivors (2017) (31)
Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease (2014) (31)
Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease. (2017) (29)
Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. (2005) (28)
Ten HLA-DR4 alleles defined by sequence polymorphisms within the DRB1 first domain (2004) (28)
Pitfalls in the design of clinical trials for prevention or treatment of acute graft-versus-host disease. (2006) (28)
Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease (2015) (28)
Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation Survivors. (2016) (28)
Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. (2011) (27)
Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects. (2013) (27)
Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation. (2015) (27)
Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. (2012) (27)
Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. (2016) (26)
Chronic graft-versus-host disease: how can we release Prometheus? (2008) (26)
Multivariate Detection of Gene‐Gene Interactions (2012) (25)
Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: potential role of a veto mechanism (1996) (25)
A new human T-cell differentiation antigen: Unexpected expression on chronic lymphocytic leukemia cells (2005) (25)
Study design and endpoints in graft-versus-host disease. (2008) (25)
Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease. (2017) (24)
Genetics of allogeneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes (2008) (24)
Medical and psychosocial issues in transplant survivors (2007) (24)
Evaluation of Thalidomide for Treatment or Prevention of Chronic Graft-versus-host Disease (2003) (23)
Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective, randomized trial (1997) (23)
Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80 (2018) (23)
Ten HLA-DR 4 alleles defined by sequence polymorphisms within the DRB 1 first domain (23)
Responsibility for costs associated with clinical trials. (2014) (22)
Simultaneous genotyping of single nucleotide polymorphisms in the IL-6, IL-10, TNFα and TNFβ genes (2002) (22)
Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease (2014) (22)
Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials. (2008) (22)
131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). (2005) (22)
Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD (2014) (21)
Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. (2020) (21)
Success of allogeneic marrow transplantation for children with severe aplastic anaemia (2012) (21)
A combined biomarker and clinical panel for chronic graft versus host disease diagnosis (2016) (20)
Activation and expansion of CD8(+) T effector cells in patients with chronic graft-versus-host disease. (2011) (20)
Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. (2018) (19)
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose (2012) (19)
Disability related to chronic graft -versus-host disease after alternative donor hematopoietic cell transplantation (2018) (19)
Overview of Hematopoietic Cell Transplantation Immunology (2009) (17)
Re: Twenty-year follow-up in patients with aplastic anemia given marrow grafts from HLA-identical siblings and randomized to receive methotrexate/cyclosporine or methotrexate alone for prevention of graft-versus-host disease. (2005) (17)
Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation (2017) (17)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. (2021) (17)
Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia. (2017) (17)
Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. (2017) (17)
A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation. (2011) (17)
Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease (2022) (16)
Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study. (2009) (16)
Application of CIBMTR risk score to NIH chronic GVHD at individual centers. (2014) (16)
Thalidomide for treatment of patients with chronic graft-versus-host disease (2000) (16)
A ricin A chain-containing immunotoxin that kills human T lymphocytes in vitro (1985) (16)
Genetic risk factors for sclerotic graft-versus-host disease. (2014) (16)
Evaluation of oral beclomethasone dipropionate for prevention of acute graft-versus-host disease. (2012) (15)
Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. (2015) (15)
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades (2020) (15)
A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT) (2016) (15)
Improving hematopoietic cell transplant outcomes in a new era of genomic research. (2009) (15)
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report. (2017) (15)
Confounding Factors Affecting the National Institutes of Health (NIH) Chronic Graft-Versus-Host Disease Organ-Specific Score and Global Severity (2016) (15)
Disability Related to Chronic Graft-Versus-Host Disease. (2020) (14)
Pilot study of lithium to restore intestinal barrier function in severe graft-versus-host disease (2017) (14)
Tissue-resident PSGL1loCD4+ T cells promote B cell differentiation and chronic graft-versus-host-disease-associated autoimmunity. (2020) (14)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. (2021) (14)
PD-L 1 interacts with CD 80 to regulate graft-versus-leukemia activity of donor CD 8 + T cells (2018) (13)
Expanding Assessments of Translational Research Programs (2014) (13)
Preincubation of donor bone marrow cells with a combination of murine monoclonal anti-T-cell antibodies without complement does not prevent graft-versus-host disease after allogeneic marrow transplantation (2004) (13)
Depletion of host CCR7(+) dendritic cells prevented donor T cell tissue tropism in anti-CD3-conditioned recipients. (2014) (13)
Frequency of abnormal findings detected by comprehensive clinical evaluation at 1 year after allogeneic hematopoietic cell transplantation. (2009) (13)
Evolution of epitopes on human and nonhuman primate lymphocyte cell surface antigens (2004) (13)
Allogeneic hematopoietic cell transplantation after conditioning with 131 I – anti-CD 45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome (2009) (12)
Keratinocyte dysplasia in hematopoietic stem cell transplantation recipients in the day-28-to-84 posttransplantation period. (2012) (12)
Engagement with INSPIRE, an Online Program for Hematopoietic Cell Transplantation Survivors. (2018) (12)
Risk Factors for the Development of Acute and National Institute of Health (NIH) Chronic Graft-Versus-Host Disease (GVHD). (2009) (12)
CD34 Cell Dose and Chronic Graft-versus-Host Disease after Human Leukocyte Antigen-Matched Sibling Hematopoietic Stem Cell Transplantation (2004) (12)
Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis. (2019) (12)
CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. (2017) (12)
Winning the battle of graft versus host (2000) (12)
Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. (2019) (11)
Long-Term Comparison of Immunosuppressive Therapy with Antithymocyte Globulin to Bone Marrow Transplantation in Aplastic Anemia (1990) (11)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. (2021) (10)
Prognostic Relevance of “Early-Onset” Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation. (2004) (10)
Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. (2019) (10)
The Future of Chronic Graft-Versus-Host Disease: Introduction to the 2020 National Institutes of Health Consensus Development Project Reports. (2021) (10)
131 I-Anti-CD45 Antibody Plus Busulfan/Cyclophosphamide in Matched Related Transplants for Acute Myeloid Leukemia in First Remission. (2004) (10)
Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation. (2020) (10)
A proposed objective way to assess results of randomized prospective clinical trials with acute graft‐versus‐host disease as an outcome of interest (2001) (10)
Low Albumin, High Ferritin, and Thrombocytopenia Before Transplant Predict Non-Relapse Mortality (NRM) Independent of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI). (2009) (10)
Unusual distribution of Ia-like antigens on canine lymphocytes (2004) (10)
PRELIMINARY RESULTS OF A PHASE II TRIAL OF IODINE-131-LABELED ANTI-CD20 (B1) ANTIBODY THERAPY WITH BONE MARROW RESCUE FOR PATIENTS WITH RELAPSED B CELL LYMPHOMAS (1994) (10)
Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. (2020) (10)
Allogeneic marrow transplantation (1993) (10)
Pathogenic neutrophils in acute GVHD. (2018) (9)
IL-22-dependent dysbiosis and mononuclear phagocyte depletion contribute to steroid-resistant gut graft-versus-host disease in mice (2021) (9)
Home Spirometry Telemonitoring for Early Detection of Bronchiolitis Obliterans Syndrome in Patients with Chronic Graft Versus Host Disease. (2021) (9)
Influence of Metabolic Traits and Lifestyle Factors on Cardiovascular Disease After Hematopoietic Cell Transplantation (2012) (8)
IL 10 AND IL 10 RECEPTOR GENE VARIATION AND OUTCOMES AFTER UNRELATED AND RELATED HEMATOPOIETIC CELL TRANSPLANTATION (2009) (8)
Reporting of adverse event data in hematopoietic stem cell transplantation clinical trials involving investigational new drugs or devices: a report from the William Guy Forbeck Foundation 2001 focus meeting on clinical trials in hematopoietic stem cell transplantation. (2002) (8)
Influence of Metabolic Traits and Lifestyle Factors on Cardiovascular Disease After Hematopoietic Cell Transplantation (2012) (8)
Role of CD 28 in Acute Graft-Versus-Host Disease (1998) (8)
Recipient and donor genetic variants associated with mortality after allogeneic hematopoietic cell transplantation. (2020) (8)
Unique sequences for two HLA-DRB1 genes expressed on distinct DRw6 haplotypes (2004) (7)
Biology and management of chronic graft-versus-host disease. (2009) (7)
Chemokine expression in Th 1 cell-induced lung injury : prominence of IFN-g-inducible chemokines (2000) (7)
Transplantation and aging. (2006) (7)
SYNERGISM BETWEEN IL-10 GENOTYPE OF PATIENT AND IL-10 RECEPTOR-β GENOTYPE OF DONOR (2005) (7)
A Multi-Center, Randomized, Double Blind, Phase III Clinical Trial Comparing Steroids/Placebo Vs. Steroids/Mycophenolate Mofetil As Initial Therapy for Acute Graft-Versus-Host Disease. Blood and Marrow Transplant Clinical Trials Network Study 0802 (2013) (7)
Phenotyping human leukemic T-Cell lines: Enzyme markers; surface antigens, and cytogenetics (2004) (7)
I-Anti-CD 45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome (1999) (7)
Endpoints for Clinical Trials Testing Treatment of Acute Graft- versus-host Disease: A Consensus Document (2010) (7)
The impact of members of the Society of University Surgeons on the scholarship of American surgery. (2016) (6)
High-Dose Radioimmunotherapy of B Cell Lymphomas1 (1989) (6)
Chronic Graft versus Host Disease: Interdisciplinary Management: Front Line Treatment of Chronic Graft versus Host Disease (2009) (6)
Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial (2016) (6)
Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity. (2021) (6)
Impact of clinical fellowships on academic productivity in departments of surgery. (2016) (6)
IgG anti-tetanus toxoid antibody synthesis by human bone marrow. I. Two distinct populations of marrow B cells and functional differences between marrow and peripheral blood B cells (1990) (6)
HLA and marrow transplants from unrelated donors (1994) (6)
The positive association of Association for Academic Surgery membership with academic productivity. (2016) (6)
Impact of Comorbidities on Early and Late Mortalities After Allogeneic Hematopoietic Cell Transplantation (HCT) (2011) (5)
Genetic Variants Associated with Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation. (2021) (5)
Association of Pre-Transplant Comorbidities with Long-Term Quality of Life (QOL) Among Survivors After Allogeneic Hematopoietic Cell Transplantation (HCT) (2013) (5)
Mantle Zone and Germinal Center B cells Respond to Different Activation Signals (1985) (5)
Choosing between GVHD and delayed engraftment (2009) (5)
Treatment of Recurrent or Persistent AML/MDS After Allogeneic Hematopoietic Cell Transplantation with Azacitidine. (2010) (4)
Relevance of plasma matrix metalloproteinase-9 for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation: Plasma MMP-9 in BOS. (2021) (4)
The Chronic Graft-vs.-Host Disease Failure-Free Survival (cGVHD-FFS) index. (2019) (4)
Efficacy and Safety Of Lower-Dose Glucocorticoids For Initial Treatment Of Acute Graft-Versus-Host Disease: A Randomized Controlled Trial (2013) (4)
Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK Pathway (2022) (4)
Seattle Symposium on Cancer Research Outcomes: Commentary on the Papers by Donaldson and Moinpour and by Osoba (2002) (4)
CIK: a path to GVL without GVHD? (2011) (4)
Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival (2021) (4)
Incidence, Risk Factors, and Prognosis of Late Immune-Mediated Disorders after Allogeneic Hematopoietic Cell Transplantation (HCT) (2015) (4)
Serious Acute or Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplantation: A Comparison of Myeloablative and Non-Myeloablative Conditioning Regimens. (2006) (4)
Effect of Peripheral Blood Stem Cell (PBSC) Graft Composition on Graft Versus Host Disease (GVHD) and Mortality After Allogeneic Transplantation (2010) (4)
Use of Flow Microfluorometry in Bone Marrow Transplantation a (1984) (4)
Multi-Institutional Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes (2011) (4)
Effect of disparity in the newly identified minor histocompatibility antigen SKH13 on the development of graft-versus-host disease after marrow transplantation from an HLA-identical sibling (2000) (4)
A Multicenter Phase I/II Study of Relapse Prophylaxis with Nilotinib after Hematopoietic Cell Transplantation (HCT) for High-Risk Philadelphia Chromosome-Positive (Ph+) Leukemias (2015) (3)
Reversing CD8+ T-cell exhaustion with DLI. (2014) (3)
Risk Factors for Graft Rejection of Marrow Transplants From HLA Haploidentical Donors (1989) (3)
A Model of Minor Histocompatibility Antigens in Allogeneic Hematopoietic Cell Transplantation (2021) (3)
Chronic GvHD NIH Consensus Project Biology Task Force: Evolving path to personalized treatment of chronic GvHD. (2022) (3)
Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes (2011) (3)
Association of plasma CD 163 concentration with de novo-onset chronic graft-versus-host disease (2017) (3)
Sitagliptin to Prevent Acute Graft-versus-Host Disease. (2021) (3)
Studies of T Cell Proliferation Induced by Monoclonal Antibodies of the Second International Workshop (1986) (3)
RADIOLABELED ANTIBODY THERAPY OF RELAPSED B CELL LYMPHOMAS (1993) (2)
Murine Models Provide New Insights Into Pathogenesis of Chronic Graft-Versus-Host Disease in Humans (2021) (2)
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Stem Cell Transplantation (2015) (2)
Outcomes among Patients with Recurrent High-Risk Hematologic Malignancy after Nonmyeloablative Versus Myeloablative Allogeneic Hematopoietic Cell Transplantation. (2006) (2)
Chapter 2 – Monoclonal Antilymphocyte Antibodies: Probes for the Study of the Regulation of Hematopoiesis and Potential Clinical Applications1 (1983) (2)
Outcome of Hematopoietic Cell Transplant from HLA-Matched Siblings Compared to a Volunteer Unrelated Donors Matched for HLA-A, B, C, DRB1, and DQB1 Alleles. (2007) (2)
Effect of HLA-DRB1 and DQB1 allele disparity on the development of acute graft versus host disease following unrelated donor marrow transplantation (1994) (2)
Confounding Factors Affecting the National Institutes of Health (NIH) Chronic GVHD Organ-Specific Score and Global Severity (2014) (2)
Bortezomib for prevention of acute graft-versus-host disease: a conclusion reached (2018) (2)
Safety and Potential Efficacy of Low Dose Methotrexate for Treatment of Chronic Graft-Versus-Host Disease. (2004) (2)
Infections Post Transplant Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation (2003) (2)
Impact of molecular histocompatibility typing on outcome of unrelated donor hematopoietic cell transplantation (2002) (2)
Encouraging Results of a Phase II Trial of Inhaled Fluticasone Propionate, Azithromycin, and Montelukast (FAM) May Maintain Lung Function in Bronchiolitis Obliterans Syndrome (BOS) after Hematopoietic Cell Transplantation (2015) (2)
Marrow Transplants from Unrelated Donors for the Treatment of High-Risk Acute Leukemia (1998) (2)
Interaction of Age and Comorbidities and Their Impacts on Hematopoietic Cell Transplantation (HCT) Outcomes (2011) (2)
Evaluation of Published Single-Nucleotide Polymorphisms (SNPs) Associated with Cytomegalovirus Infection and Disease after Hematopoietic Cell Transplantation in a Large Caucasian Cohort (2014) (2)
Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease. (2019) (2)
Immune Rejection: The Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation (from Mice to Humans) (2013) (2)
ANG2/VEGF in steroid-refractory GVHD. (2011) (2)
Comparison of Tacrolimus Versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia: A CIBMTR Analysis (2014) (1)
Allogeneic and Syngeneic Marrow Transplantation for Aplastic Anemia: Overview of Seattle (1988) (1)
Falling Serum Albumin Predicts Severity of Acute Graft-Vs.-Host Disease and Non-Relapse Mortality After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation. (2009) (1)
Quality of Life and Chronic Gvhd Severity According to the NIH Criteria: Results From the Chronic Gvhd Consortium (2010) (1)
Survival without Progressive Impairment As a Novel Endpoint in Chronic Graft-Versus-Host Disease (2015) (1)
Failure-Free Survival After Initial Systemic Treatment Of Chronic GVHD (2013) (1)
Statins Synergize With Cyclosporine in Inhibiting Mitochondrial Function in Activated T Cells (2011) (1)
Impact of Pre-Transplant Comorbidities on the Rate of- and Mortality-Following Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation (HCT) (2011) (1)
Identification of Modifiable Factors Associated with Lower Adherence to Preventive Care Practices In HCT Survivors. (2010) (1)
Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin (2021) (1)
MEKing it easier to prevent GVHD. (2013) (1)
Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease after HLA-Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation (2016) (1)
47: Prospective Neurocognitive Function and Risk Factors at 5 Years After Allogeneic Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies, Compared with Controls at 5 Years (2008) (1)
Efficacy of Remestemcel-L Treatment in Steroid Refractory Acute Graft-Versus-Host Disease in Children: An Aggregate Analysis (2020) (1)
Association of IL-10 and IL-10 Receptor Gene Polymorphisms and Graft-Versus-Host Disease Following Hematopoietic Cell Transplantation. (2004) (1)
Retransplantation of marrow and hematopoietic stem cells from normal donors (1997) (1)
Rare Variant Genetic Association Study for Transplant-Associated Thrombotic Microangiopathy (TA-TMA) Via Whole Exome Sequencing (2021) (1)
A Biomarker Panel for Chronic Graft-Versus-Host Disease (2015) (1)
Frequency and Intensity of Antibody Responses to Antigens Encoded by KDM5D (SMCY) and Other H-Y Genes After Allogeneic Hematopoietic Cell Transplantation, (2011) (1)
Correlation Between Severity of Oral Mucositis and Both Overall and Gut Acute GvHD After High Intensity Conditioning Hematopoietic Stem Cell Transplantation. (2012) (1)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report Transplantation and Cellular Therapy (2021) (1)
HISTOPATHOLOGIC DIAGNOSIS OF CHRONIC GRAFT VERSUS HOST DISEASE 2014 NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: II. Pathology Working Group Report (2006) (1)
Change in NIH Skin Score 0–3 Correlates with Provider- and Patient-Reported Skin Changes and Overall Survival: Results From the Chronic Gvhd Consortium (2011) (1)
Calculated NIH Response Correlates with Changes in Patient-Reported Symptoms but Not with Quality of Life: Results From the Chronic Gvhd Consortium (2011) (1)
Clinical Research 1016 Use of Fluid-Ventilated, Gas-Permeable Scleral Lens for Management of Severe Keratoconjunctivitis Sicca Secondary to Chronic Graft-versus-Host Disease (2007) (1)
Hardy's "Small" Discovery Remembered. (2008) (1)
Regional Analysis of Candidate Genes Associated With Acute GVHD Following Allogeneic Hematopoietic Cell Transplantation (2011) (1)
Trafficking between clonally related peripheral T helper cells and tissue-resident T helper cells in chronic GVHD. (2022) (1)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report Transplantation and Cellular Therapy (2021) (1)
Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease (2022) (1)
20. Risk Factors for Breakthrough Cytomegalovirus (CMV) Infection and De Novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis (2021) (1)
Graft-Versus-Host Disease in Mice CD28-Specific Antibody Prevents (2017) (1)
Pre-Transplant Ferritin, Albumin and Platelet Count Add Prognostic Information to Comorbidities for Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes: A Multi-Center Discovery-Validation Study (2014) (1)
Clinical manifestation of chronic graft-versus-host disease (cGVHD) after transplantation of peripheral blood stem cell (PBSC) compared to bone MARROW (BM) (2000) (1)
434 Association of skin response in erythema and sclerosis with survival in chronic graft-versus-host disease (2020) (1)
The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation (2012) (1)
Response to Krejci and Mayer (2010) (1)
Durable Discontinuation of Immunosuppressive Therapy (IST): Clinical Results from the Chronic GvHD Consortium (2021) (1)
Cell biology comes to the bedside (2007) (1)
ncreasingly Frequent Diagnosis of Acute astrointestinal Graft-versus-Host Disease after llogeneic Hematopoietic Cell Transplantation (2004) (1)
Selected reviews from the 2014 BMT Tandem meetings [corrected]. (2014) (1)
Cyclosporine (CSP) or CSP plus methylprednisolone for graft-versus-host- disease prophylaxis in patients with high-risk lymphohemopoietic malignancies (2000) (1)
HISTOPATHOLOGIC DIAGNOSIS OF CHRONIC GRAFT VERSUS HOST DISEASE: NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: II. The 2014 Pathology Working Group Report (2015) (1)
Chapter 18. Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation (2007) (1)
Risk Factors for Depression and Fatigue Among Hematopoietic Cell Transplant (HCT) Recipients (2015) (1)
Neutralizing IL-2 Early after HCT Specifically Prevents Expansion of Donor GM-CSF-Producing CD4+ T Cells That Initiate Acute Gut Gvhd (2018) (0)
A Phase II Study of Bandage Contact Lenses for Ocular Graft-Versus-Host Disease (2015) (0)
Changes in CD4+ T Cells and Regulatory T Cells (Treg) in Chronic Graft-Versus-Host Disease (cGVHD) (2011) (0)
chronic GVHD Evaluation of NIH consensus criteria for classification of late acute and (2009) (0)
Lithium attenuates graft-versus-host disease via effects on the intestinal stem cell niche. (2022) (0)
Treatment of Chronic Graft-versus-Host Disease - Progress to Date and Challenges Ahead (2019) (0)
Stat3-/- Alloreactive Donor T Cells Reduce FAO but Increase Leakage of ROS in Response to PD-1 Signaling Triggered By Host-Tissue PD-L1, Leading to Prevention of Gvhd While Preserving GVL Effect (2019) (0)
Targeting Intestinal Epithelial Ceacam1 Expands Peripheral Tregs and Prevents Steroid-Refractory Acute Gut Graft-Versus-Host Disease (2022) (0)
Immunogenetics of allogeneic hematopoietic transplantation (1996) (0)
Physician-Reported CR+PR at 6 Months Predicts Subsequent Survival in Patients with Chronic GVHD (2015) (0)
Elimiation of PDGF-B from only the circulating cells of APOE −/− mice significantly impacts atherosclerotic lesion formation (2000) (0)
Comorbidity Indexes and Allogeneic Stem Cell Transplantation (SCT). (2007) (0)
regimens after hematopoietic cell transplantation with myeloablative conditioning An acute graft-versus-host disease activity index to predict survival (2010) (0)
ncillary Therapy and Supportive Care of Chronic raft-versus-Host Disease : National Institutes of ealth Consensus Development Project on Criteria or Clinical Trials in Chronic Graft-versus-Host isease : V . Ancillary Therapy and Supportive Care orking Group Report (2006) (0)
Chronic graft-versus-host-disease treatment in Brazil: analyses of failure-free survival. (2023) (0)
Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease (2017) (0)
Pulmonary symptoms measured by the NIH Lung score predict overall survival, non-relapse mortality and patient-reported outcomes in chronic GVHD (2014) (0)
Gene Expression in CD4+ T Cells of Patients With and Without Chronic Graft-Vs-Host Disease (cGVHD) (2011) (0)
Allogeneic Marrow Graft Rejection Involvement of Donor T-Cell Cytotoxic Effector Mechanisms in Preventing (1998) (0)
Elements compositional detection system and method (2010) (0)
Chronic Graft versus Host Disease: Interdisciplinary Management: Design of Clinical Trials Testing Treatment for Chronic Graft versus Host Disease (2009) (0)
Comparison between short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease (2011) (0)
Prognostic Factors and Outcomes of Severe Gastrointestinal Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation (2008) (0)
A Retrospective Comparison of Tacrolimus Vs. Cyclosporine for Immunosuppression After Allogeneic Hematopoietic Cell Transplantation with G-CSF-Mobilized Blood Cells (2010) (0)
How I Treat How we treat chronic graft-versus-host disease (2015) (0)
Myeloablative Transplant (HCT) (2012) (0)
HLA Typing in Support of Hematopoietic Cell Transplantation from Unrelated Donors (2013) (0)
Extrafollicular CD4+ T and B Interaction Induces Chronic Gvhd in the Absence of Germinal Center Formation (2015) (0)
FAM treatment for new onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation (2016) (0)
Host Tissue PD-L1 Separates GVL Effect from Gvhd after Temporary Depletion of Donor CD4 + T Cells Early after HCT (2015) (0)
Posttransplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after HLA-Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation (2014) (0)
Prediction of outcomes after second-line treatment for acute graft-versus-host disease (2022) (0)
-inducible chemokines γ prominence of IFN- Chemokine expression in Th1 cell-induced lung injury: (2016) (0)
Pulmonary Symptoms Measured by the NIH Lung Score Predict Overall Survival and Non-Relapse Mortality in Chronic GVHD (2013) (0)
Tissue-Resident PSGL1loCD4+ T Cells Interact with B Cells Via PD-1 and PD-L2 in Gvhd Target Tissues to Augment Autoimmune-like Chronic Gvhd (2019) (0)
Tc17 cells cause gut graft-versus-host disease through induction of dysbiosis and depletion of CX3CR1hi phagocytes (2020) (0)
Seattle Symposium on Cancer Research Outcomes (2002) (0)
Clinical Marrow Transplantation (1987) (0)
hematopoietic stem cell transplantation Graft-versus-host disease after nonmyeloablative versus conventional (2014) (0)
Comorbidity Burden in Patients with Chronic Graft Versus Host Disease (2014) (0)
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Consensus Recommendations for Research Methodology and Study Design (2016) (0)
Obligation for transparency regarding treating physician credentials at academic health centres (2018) (0)
Association of Graft-Versus-Host Disease and Immunosuppressive Treatment with Risks of Recurrent Malignancy and Mortality After Allogeneic Hematopoietic Cell Transplantation (2010) (0)
Association Between AGT SNPs, Plasma AGT Levels, and Risk for IPS After Allogeneic HCT (2013) (0)
disease: a multicenter study Performance of a new clinical grading system for chronic graft-versus-host (2013) (0)
Expansion of Th/Tc17 T Cells and Loss of CX3CR1+ Macrophages Play a Critical Role in the Pathogenesis of Steroid-Refractory Acute Intestinal Gvhd (2019) (0)
B itfalls in the Design of Clinical Trials for Prevention r Treatment of Acute Graft-versus-Host Disease (2006) (0)
Genetic variants associated with inflammatory bowel disease and gut graft-versus-host disease (2021) (0)
allogeneic hematopoietic stem cells Conditioning with fludarabine and targeted busulfan for transplantation of (2013) (0)
Tissue Parenchymal Cell Expression of B7-H1 Inhibits Infiltrating T Cell Expansion and Prevents Persistence of Graft-Versus-Host Disease (2011) (0)
Myelodysplastic Syndrome : The Transplanter ’ s Quandaries (2008) (0)
SPECIFIC IgG ANTI-TETANUS TOXOID ANTIBODY SYNTHESIS BY HUMAN BOA MARROW MONONUCLEAR CELLS (1987) (0)
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Followed by Bortezomib Maintenance Therapy for High Risk Multiple Myeloma (2017) (0)
Laboratory Correlates of Immune Reconstitution At 1-Year Following Related, Unrelated, and Umbilical Cord Blood Hematopoietic Stem Cell Transplantation: Correlation with Survival (2013) (0)
Association of Comorbidity Scoring with Outcome in Patients with Chronic Graft Versus Host Disease (2013) (0)
A Refined Clinical Risk Score at Onset of Treatment for Acute Gvhd That Predicts Response to Initial Therapy, Survival and Transplant-Related Mortality (2014) (0)
Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease. (2023) (0)
Predictors of acute GVHD treatment outcomes 1 PREDICTIVE VALUE OF CLINICAL FINDINGS AND PLASMA BIOMARKERS AFTER 14 DAYS OF PREDNISONE TREATMENT FOR ACUTE GRAFT-VERSUS-HOST DISEASE (2017) (0)
Analysis of Pulmonary Function Change Associated with Sclerotic Chronic Graft Versus Host Disease (ScGVHD) (2017) (0)
Initial Systemic Therapy of Chronic Graft Vs. Host Disease: Analysis of Practice Variation and Failure-Free Survival (2021) (0)
Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplant and investigation into BOS pathogenesis. (2022) (0)
genotype of donor β synergism between IL-10 genotype of patient and IL-10 receptor graft-versus-host disease following hematopoietic cell transplantation: Genetic variation in the IL-10 pathway modulates severity of acute (2013) (0)
Risk Factors for Late Cardiovascular Morbidity and Mortality After Hematopoietic Cell Transplantation (2011) (0)
Graft-Versus-Host Disease: A Prospective, Randomized Trial Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of (2011) (0)
Influence Of Organ Scores On Mortality In Chronic GVHD: Results From The Chronic GVHD Consortium (2013) (0)
Chronic Cutaneous GVHD Does Not Correlate with Frequency and FoxP3 Gene Expression of Regulatory T Cells. (2005) (0)
Educating Radiologists for Self-governance. (2018) (0)
Change of Treatment for Control of Chronic Graft-Versus-Host Disease (cGVHD) as a Time-Dependent Covariate for Nonrelapse Mortality and Survival. (2007) (0)
Genetic associations with immune-mediated outcomes after allogeneic hematopoietic cell transplantation (2022) (0)
Frequent Eczematous Dermatitis in Unrelated Cord Blood Hematopoietic Cell Transplant Recipients Compared With Other Donor Types Transplantation and Cellular Therapy (2021) (0)
Risk Factors for Musculoskeletal Symptoms in 5-20 Year Survivors Who Received Myeloablative Hematopoietic Cell Transplant (HCT) (2014) (0)
Immunologic regulation of allogeneic marrow engraftment (1996) (0)
High Dose Radiolabeled Antibody Therapy of Lymphoma 1 (2006) (0)
A Pilot Study Evaluating the Safety and Efficacy of Imatinib Given Early after Transplant for High-Risk Philadelphia Chromosome-Postive Leukemias. (2005) (0)
Activation of Alveolar Macrophages Mononuclear Cell Inflammation and Cells Is Characterized by Host-Derived Lung Injury Induced by Alloreactive Th 1 (1998) (0)
Stat3 Regulates Alloreactive T Cell Susceptibility Towards PD-L1-Mediated Tolerance Signaling, Gvhd and GVL Activity (2018) (0)
TCR-MHC-peptide(s): in vivo veritas. (2011) (0)
Incidence, Risk Factors and Outcomes of Sclerotic Chronic Graft-Versus-Host Disease (GVHD) Phenotype After Allogeneic Hematopoietic Cell Transplantation (2011) (0)
Neutralization of IL-2 prevents acute GVHD while preserving GVL activity via regulating PD-L1/PD-1 signaling (2019) (0)
S1P/S1PR1 Signalis Required for Optimal T-Cell Pathogenicity to Induce Gvhd By RegulatingDrp1/mTOR Axis (2021) (0)
Two monoclonal murine antibodies that detect the human T cell E-rosette receptor: A comparative analysis (1982) (0)
Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity (2023) (0)
Progress in chronic graft-versus-host disease (2011) (0)
Graft-Versus-Host Reaction T Cells in the + Antigen-Specific CD 8 Visualization , Fate , and Pathogenicity of Anasetti (1999) (0)
Antithymocyte Globulin Aplastic Anemia Conditioned by Cyclophosphamide Combined With Long-Term Follow-Up of Allogeneic Marrow Transplants in Patients With (2011) (0)
Cytomegalovirus breakthrough and resistance during letermovir prophylaxis (2023) (0)
Utility of Grip Strength and 2 Minute Walk Test in Chronic GVHD Assessment: An Analysis From the Chronic GVHD Consortium (2013) (0)
Predominant Pulmonary Vasculitis CD 45 Induce Graft-Versus-Host Disease with T Cells Specific for a Polymorphic Segment of Kusunoki (1998) (0)
Allogeneic hematopoietic stem cell transplantation for myeloﬁbrosis (2003) (0)
Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium (2010) (0)
TRANSPLANTATION Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease (2013) (0)
Spiritual/religious struggle in hematopoietic cell transplant survivors. (2013) (0)
Characterization of Chronic Graft-Versus-Host Disease and Duration of Immunosuppression After Cord Blood Transplantation, (2011) (0)
Immune Correlates from a Prospective Trial Suggest Leukotriene Signaling and Alternative Macrophage Activation in Clinical Bronchiolitis Obliterans Syndrome (2021) (0)
Recommended Tools for Joint Chronic Graft-Versus-Host Disease: Results From the Chronic Gvhd Consortium (2012) (0)
Late Cardiovascular Morbidity Following Pediatric Allogeneic Hematopoietic Cell Transplantation (2016) (0)
Response Endpoints for Acute Graft-Versus-Host Disease Treatment Trials (2013) (0)
Pretreatment with Anti-CD3 Monoclonal Antibody Depletes Recipient CCR7+ Dendritic Cells and Prevents Graft-Versus-Host Disease While Preserving GVL Effects, (2011) (0)
Analysis of CD4 Gene Expression in Hematopoietic Cell Transplant (HCT) Tolerant Patients (141.20) (2009) (0)
Comparison of Proposed NIH Response Criteria with Clinician-Reported Changes in Organ-Specific and Overall Response (2011) (0)
Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic GVHD (2019) (0)
Infusions Disease Mediated by Donor Leukocyte Host T Cells Resist Graft-Versus-Host (2000) (0)
New Strategies for Fungal Infections after Hematopoietic Cell Transplantation : Prevention or Preemption ? (2007) (0)
Feasibility of home spirometry in patients with chronic graft-versus-host disease: a prospective observational study (2020) (0)
Engraftment, Graft Rejection, and Graft Failure (2019) (0)
Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD) (2022) (0)
Indirect Effects of Cytomegalovirus Infection After Hematopoietic Cell Transplantation in the Preemptive Therapy Era (2015) (0)
Persistence of Graft-Versus-Host Disease T Cells and + Infiltrating Donor CD 8 Parenchymal Cells Leads to Expansion of Loss of B 7-H 1 Expression by Recipient (2011) (0)
Pathway-driven rare germline variants associated with transplant-associated thrombotic microangiopathy (TA-TMA). (2023) (0)
Chromosome-Positive Acute Lymphoblastic Leukemia Marrow Transplants From Unrelated Donors for Treatment of Philadelphia (2011) (0)
hematopoietic cell transplantation Risk factors for lymphoproliferative disorders after allogeneic (2013) (0)
Association of Socioeconomic Status (SES) with Chronic Graft-Versus-Host Disease (cGVHD) Outcomes (2017) (0)
Classic Papers and Current Comments Highlights of Leukemia Research (2002) (0)
bone marrow transplantation Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic (2011) (0)
Frequent Eczematous Dermatitis in Unrelated Cord Blood Hematopoietic Cell Transplant Recipients Compared to Other Donor Types. (2021) (0)
Prospective Phase Ii Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bos Pathogenesis (2021) (0)
prednisone does not compromise patient outcomes Initial therapy of acute graft-versus-host disease with low-dose (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Paul J Martin?

Paul J Martin is affiliated with the following schools:

Paul J Martin's Academic­Influence.com Rankings

Paul J Martin's Degrees

Similar Degrees You Can Earn

Why Is Paul J Martin Influential?

Paul J Martin's Published Works

Published Works

What Schools Are Affiliated With Paul J Martin?

Paul J Martin's AcademicInfluence.com Rankings